AIRLINK 62.30 Decreased By ▼ -0.18 (-0.29%)
BOP 5.35 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.47 Decreased By ▼ -0.11 (-2.4%)
DFML 15.54 Increased By ▲ 0.04 (0.26%)
DGKC 65.40 Decreased By ▼ -1.00 (-1.51%)
FCCL 17.60 Increased By ▲ 0.01 (0.06%)
FFBL 27.68 Decreased By ▼ -0.02 (-0.07%)
FFL 9.30 Increased By ▲ 0.03 (0.32%)
GGL 9.99 Decreased By ▼ -0.07 (-0.7%)
HBL 105.00 Decreased By ▼ -0.70 (-0.66%)
HUBC 121.24 Decreased By ▼ -1.06 (-0.87%)
HUMNL 6.55 Decreased By ▼ -0.05 (-0.76%)
KEL 4.45 Decreased By ▼ -0.05 (-1.11%)
KOSM 4.47 Decreased By ▼ -0.01 (-0.22%)
MLCF 35.70 Decreased By ▼ -0.50 (-1.38%)
OGDC 122.45 Decreased By ▼ -0.47 (-0.38%)
PAEL 22.65 Decreased By ▼ -0.35 (-1.52%)
PIAA 31.54 Increased By ▲ 2.20 (7.5%)
PIBTL 5.77 Decreased By ▼ -0.03 (-0.52%)
PPL 107.00 Decreased By ▼ -0.50 (-0.47%)
PRL 27.19 Decreased By ▼ -0.06 (-0.22%)
PTC 18.40 Increased By ▲ 0.33 (1.83%)
SEARL 52.49 Decreased By ▼ -0.51 (-0.96%)
SNGP 62.55 Decreased By ▼ -0.66 (-1.04%)
SSGC 10.55 Decreased By ▼ -0.25 (-2.31%)
TELE 9.22 Increased By ▲ 0.02 (0.22%)
TPLP 11.30 Decreased By ▼ -0.14 (-1.22%)
TRG 70.00 Decreased By ▼ -0.86 (-1.21%)
UNITY 23.58 Decreased By ▼ -0.04 (-0.17%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
BR100 6,924 Decreased By -19.5 (-0.28%)
BR30 22,683 Decreased By -144.2 (-0.63%)
KSE100 66,988 Decreased By -154 (-0.23%)
KSE30 22,064 Decreased By -26.3 (-0.12%)
Editorials

Renowned cancer-fighting protein can also boost cancer growth: study

A new study has challenged the fact that a widely known human protein that was previously thought to help fight can
Published February 2, 2019 Updated February 7, 2019

A new study has challenged the fact that a widely known human protein that was previously thought to help fight cancer can even boost the tumor growth too.

Scientists from University of California San Diego have carried out a new study challenging the description of the human protein ‘p53’ that is renowned for its cancer-fighting abilities, leading to its popular title as ‘the guardian of the genome’.

“The widely accepted idea is that p53 suppresses cancer, but in our study we would argue against that. In some cancers it would have the opposite effect by promoting cancer,” said researcher Yang Xu.

Smart cancer pills track patients with tiny sensors in their medicines

Studying the ‘wild type’ version of p53 – WTp53 – that is present widely in nature, the team found evidences that in some cases, the protein instead promotes tumors rather than suppressing them. The finding explains the established enigma that though p53 is mutated in over 50% of all human cancers, it is not frequently mutated in some cancers such as liver cancer.

Over four years research on liver cancer showed that WTp53 stimulates tumor growth by enhancing cancer metabolism. The key, as the researchers explain, is a protein called PUMA, which works inside the energy hub of cells – the mitochondria.

They found that at appropriate levels, PUMA disrupts normal function of mitochondria and causes a switch from oxidative phosphorylation – process for efficient energy production in cells – to glycolysis – alternative energy path that helps boost cancer metabolism.

“It’s actually the same function but playing exactly the opposite role in two different contexts,” said Xu publishing their study in the journal Cancer Cell.

Xu notified that the research provides a warning for cancer drug discovery. Drug therapies designed to improve p53’s function in cancer patient might be inadvertently causing an opposite effect, wrote Science Daily.

Copyright Business Recorder, 2019

Comments

Comments are closed.